You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 1
  • P06.03 Bispecific antibody-driven synthetic agonistic receptor engineered T cells lead to specific and conditional therapy in melanoma cancer models

Article info

Article menu

Download PDFPDF

Poster Presentations
P06 Cell Therapy in Solid Tumors
P06.03 Bispecific antibody-driven synthetic agonistic receptor engineered T cells lead to specific and conditional therapy in melanoma cancer models
Free

Authors

  • M Benmebarek Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles
  • F Märkl Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles
  • J Keyl Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles
  • B Loureiro Cadilha Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles
  • M Geiger Roche Innovation Center Zurich, Schlieren, Switzerland PubMed articlesGoogle scholar articles
  • C Karches Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles
  • S Endres Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles
  • C Klein Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles
  • S Kobold Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles
  • A Klüver Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles
  • M Schwerdtfeger Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany PubMed articlesGoogle scholar articles

Citation

Benmebarek M, Märkl F, Keyl J, et al
P06.03 Bispecific antibody-driven synthetic agonistic receptor engineered T cells lead to specific and conditional therapy in melanoma cancer models
Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-ITOC8.37

Publication history

  • First published October 6, 2021.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.